Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308752919> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4308752919 abstract "Background and Purpose: S1P receptors control endothelial cell proliferation, migration, and survival. Evidence of the ability of S1P receptor modulators to influence multiple endothelial cell functions suggests their potential use for antiangiogenic effect. The main purpose of our study was to investigate the potential of siponimod for the inhibition of ocular angiogenesis in vitro and in vivo. Experimental Approach: We investigated the effects of siponimod on the metabolic activity (MTT assay), basal proliferation and growth factor induced proliferation (BrdU assay), and migration (transwell migration assay) of human umbilical vein endothelial cells (HUVEC) and retinal microvascular endothelial cells (HRMEC). The effects of siponimod on HRMEC monolayer integrity, and barrier function under basal conditions and TNF-α induced disruption were assessed using the trans-endothelial electrical resistance (TEER) and FITC-dextran permeability assays. Siponimod’s effect on TNF-α induced claudin-5 distribution in HRMEC was investigated using immunofluorescence. Finally, the effect of siponimod on ocular neovascularization in vivo was assessed using suture-induced corneal neovascularization in albino rabbits. Key Results: Siponimod did not affect endothelial cell proliferation or metabolic activity, but significantly inhibited endothelial cell migration, increased HRMEC barrier integrity, and reduced TNF-α induced barrier disruption. Siponimod also protected against TNF-α induced disruption of claudin-5 in HRMEC. These actions are mainly mediated by S1PR1 receptor modulation. Finally, siponimod prevented the progression of suture-induced corneal neovascularization in albino rabbits. Conclusion and Implications: The effects of siponimod on various processes known to be involved in angiogenesis support its therapeutic potential in disorders associated with ocular neovascularization." @default.
- W4308752919 created "2022-11-15" @default.
- W4308752919 creator A5003661983 @default.
- W4308752919 creator A5015977155 @default.
- W4308752919 creator A5022183449 @default.
- W4308752919 creator A5041862639 @default.
- W4308752919 creator A5048223906 @default.
- W4308752919 date "2022-11-10" @default.
- W4308752919 modified "2023-10-14" @default.
- W4308752919 title "Siponimod as a novel inhibitor of retinal angiogenesis: in vitro and in vivo evidence of therapeutic efficacy" @default.
- W4308752919 doi "https://doi.org/10.22541/au.166805486.60368369/v1" @default.
- W4308752919 hasPublicationYear "2022" @default.
- W4308752919 type Work @default.
- W4308752919 citedByCount "0" @default.
- W4308752919 crossrefType "posted-content" @default.
- W4308752919 hasAuthorship W4308752919A5003661983 @default.
- W4308752919 hasAuthorship W4308752919A5015977155 @default.
- W4308752919 hasAuthorship W4308752919A5022183449 @default.
- W4308752919 hasAuthorship W4308752919A5041862639 @default.
- W4308752919 hasAuthorship W4308752919A5048223906 @default.
- W4308752919 hasBestOaLocation W43087529191 @default.
- W4308752919 hasConcept C123012128 @default.
- W4308752919 hasConcept C137738243 @default.
- W4308752919 hasConcept C140800825 @default.
- W4308752919 hasConcept C146285616 @default.
- W4308752919 hasConcept C1491633281 @default.
- W4308752919 hasConcept C150903083 @default.
- W4308752919 hasConcept C167734588 @default.
- W4308752919 hasConcept C185592680 @default.
- W4308752919 hasConcept C202751555 @default.
- W4308752919 hasConcept C207001950 @default.
- W4308752919 hasConcept C2777025900 @default.
- W4308752919 hasConcept C2777834122 @default.
- W4308752919 hasConcept C2778271429 @default.
- W4308752919 hasConcept C2780394083 @default.
- W4308752919 hasConcept C502942594 @default.
- W4308752919 hasConcept C55493867 @default.
- W4308752919 hasConcept C86803240 @default.
- W4308752919 hasConcept C95444343 @default.
- W4308752919 hasConcept C98274493 @default.
- W4308752919 hasConceptScore W4308752919C123012128 @default.
- W4308752919 hasConceptScore W4308752919C137738243 @default.
- W4308752919 hasConceptScore W4308752919C140800825 @default.
- W4308752919 hasConceptScore W4308752919C146285616 @default.
- W4308752919 hasConceptScore W4308752919C1491633281 @default.
- W4308752919 hasConceptScore W4308752919C150903083 @default.
- W4308752919 hasConceptScore W4308752919C167734588 @default.
- W4308752919 hasConceptScore W4308752919C185592680 @default.
- W4308752919 hasConceptScore W4308752919C202751555 @default.
- W4308752919 hasConceptScore W4308752919C207001950 @default.
- W4308752919 hasConceptScore W4308752919C2777025900 @default.
- W4308752919 hasConceptScore W4308752919C2777834122 @default.
- W4308752919 hasConceptScore W4308752919C2778271429 @default.
- W4308752919 hasConceptScore W4308752919C2780394083 @default.
- W4308752919 hasConceptScore W4308752919C502942594 @default.
- W4308752919 hasConceptScore W4308752919C55493867 @default.
- W4308752919 hasConceptScore W4308752919C86803240 @default.
- W4308752919 hasConceptScore W4308752919C95444343 @default.
- W4308752919 hasConceptScore W4308752919C98274493 @default.
- W4308752919 hasLocation W43087529191 @default.
- W4308752919 hasOpenAccess W4308752919 @default.
- W4308752919 hasPrimaryLocation W43087529191 @default.
- W4308752919 hasRelatedWork W1985596025 @default.
- W4308752919 hasRelatedWork W2090763994 @default.
- W4308752919 hasRelatedWork W2101045242 @default.
- W4308752919 hasRelatedWork W2102140960 @default.
- W4308752919 hasRelatedWork W2141571435 @default.
- W4308752919 hasRelatedWork W2350121500 @default.
- W4308752919 hasRelatedWork W2886608558 @default.
- W4308752919 hasRelatedWork W2962859037 @default.
- W4308752919 hasRelatedWork W4297183480 @default.
- W4308752919 hasRelatedWork W2782089469 @default.
- W4308752919 isParatext "false" @default.
- W4308752919 isRetracted "false" @default.
- W4308752919 workType "article" @default.